title: Cell-based neurotrophin treatment supports long-term auditory neuron survival in the deaf guinea pig.
abstract: The cochlear implant provides auditory cues to profoundly deaf patients by electrically stimulating the primary auditory neurons (ANs) of the cochlea. However, ANs degenerate in deafness; the preservation of a robust AN target population, in combination with advances in cochlear implant technology, may provide improved hearing outcomes for cochlear implant patients. The exogenous delivery of neurotrophins such as brain-derived neurotrophic factor (BDNF) and neurotrophin-3 is well known to support AN survival in deafness, and cell-based therapies provide a potential clinically viable option for delivering neurotrophins into the deaf cochlea. This study utilized cells that were genetically modified to express BDNF and encapsulated in alginate microspheres, and investigated AN survival in the deaf guinea pig following (a) cell-based neurotrophin treatment in conjunction with chronic electrical stimulation from a cochlear implant, and (b) long-term cell-based neurotrophin delivery. In comparison to deafened controls, there was significantly greater AN survival following the cell-based neurotrophin treatment, and there were ongoing survival effects for at least six months. In addition, functional benefits were observed following cell-based neurotrophin treatment and chronic electrical stimulation, with a statistically significant decrease in electrically evoked auditory brainstem response thresholds observed during the experimental period. This study demonstrates that cell-based therapies, in conjunction with a cochlear implant, shows potential as a clinically transferable means of providing neurotrophin treatment to support AN survival in deafness. This technology also has the potential to deliver other therapeutic agents, and to be used in conjunction with other biomedical devices for the treatment of a variety of neurodegenerative conditions.
authors.affiliation: Bionics Institute, Australia; Department of Medical Bionics, The University of Melbourne, Australia. Electronic address: lgillespie@bionicsinstitute.org.
authors.forename: Lisa N
authors.initials: LN
authors.lastname: Gillespie
authors.affiliation: Bionics Institute, Australia.
authors.forename: Mark P
authors.initials: MP
authors.lastname: Zanin
authors.affiliation: Bionics Institute, Australia; Department of Medical Bionics, The University of Melbourne, Australia.
authors.forename: Robert K
authors.initials: RK
authors.lastname: Shepherd
mesh_terms: D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000008:administration & dosage* / Q000235:genetics / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D064987:Cell- and Tissue-Based Therapy; D003054:Cochlear Implants; D016503:Drug Delivery Systems; D004558:Electric Stimulation; D005260:Female; D005347:Fibroblasts / Q000378:metabolism*; D006168:Guinea Pigs; D006319:Hearing Loss, Sensorineural / Q000601:surgery / Q000628:therapy*; D008297:Male; D009474:Neurons / Q000187:drug effects; D051381:Rats
chemical_list: D019208:Brain-Derived Neurotrophic Factor
keywords: BDNF; Cell encapsulation; Cell therapy; Cochlear implant; Deafness